Biogen Inc. $BIIB Shares Purchased by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 129.0% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 7,928 shares of the biotechnology company’s stock after acquiring an additional 4,466 shares during the period. Banque Cantonale Vaudoise’s holdings in Biogen were worth $1,453,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BIIB. Norges Bank purchased a new position in Biogen in the 4th quarter valued at about $464,408,000. Boston Partners acquired a new position in shares of Biogen during the fourth quarter valued at approximately $302,815,000. Fred Alger Management LLC lifted its position in shares of Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after acquiring an additional 796,735 shares in the last quarter. Employees Provident Fund Board acquired a new stake in shares of Biogen in the fourth quarter worth approximately $123,931,000. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after acquiring an additional 509,809 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BIIB. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research note on Monday. HC Wainwright reaffirmed a “buy” rating on shares of Biogen in a research note on Thursday, May 14th. Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Needham & Company LLC reiterated a “buy” rating on shares of Biogen in a research report on Thursday, June 18th. Finally, Guggenheim raised their price target on shares of Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $217.37.

Biogen Price Performance

Biogen stock opened at $216.03 on Friday. The company’s 50 day simple moving average is $193.37 and its 200-day simple moving average is $185.67. The company has a market capitalization of $31.89 billion, a price-to-earnings ratio of 23.18 and a beta of 0.20. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $218.06. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts expect that Biogen Inc. will post 13.95 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.